USACTNM▼
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results and Affirms Key Clinical Milestones
Contineum Therapeutics reported its second-quarter 2026 financial results and affirmed key clinical development milestones. The company's cash, cash equivalents and marketable securities totaled $236.6 million as of June 30, 2026, which it believes is sufficient to fund operations through mid-2029. Research and development expenses decreased 10 percent to $12.7 million, while general and administrative expenses rose 23 percent to $4.7 million, resulting in a net loss of $15.2 million for the quarter. On the clinical front, Contineum's global Phase 2 PROPEL-IPF trial evaluating PIPE-791 for idiopathic pulmonary fibrosis has more than 55 sites online across eight countries, and Johnson & Johnson completed enrollment of 107 participants in its Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder. The company also streamlined its discovery programs, leading to a limited workforce reduction including the departure of its Chief Scientific Officer.